Category: Pharmacotherapy -Interventional Aspects
Background: Patients on chronic clopidogrel therapy (CCT) presenting with acute coronary syndrome (ACS) who are undergoing percutaneous coronary Intervention (PCI) are subjected to an increase risk due to lack of platelet responsiveness. This study aimed to evaluate whether there is additional benefit of reloading with clopidogrel in patients who present with ACS.
Methods:
A cohort of 1392 patients on CCT (> 5 days) who presented with ACS and received at least 1 DES were identified and were followed clinically up to 1 year. Of these 858 patients were reloaded with ≥ 300 mg of clopidogrel and 534 continued on maintenance dose. All patients continued CCT of 75 mg /day in addition to aspirin. Patients with cardiogenic shock and vein graft intervention were excluded.
Results:
The baseline characteristics and the use of bivalirudin, heparin, and glycoprotein IIb/IIIa inhibitors were similar (see Table) . The in-hospital and I year composite of major cardiac events (MACE) were similar without an increase in bleeding rate in both groups. However, there was an increase in stent thrombosis in patients who were not reloaded with clopidogrel (2.6% vs 0.4%, p=0.037) Conclusions: Clopidogrel re-loading in patients with ACS subjected to PCI is safe, but does not impact in-hospital and one year clinical events. 
